Lindbrook Capital’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Lindbrook Capital’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-70	Closed	-$294	–	2917
2023 Q1	$294	Sell	70 -305	-81%	-$1.58K	﹤0.01%	2679
2022 Q4	$2.25K	Buy	375 +305	+436%	+$1.67K	﹤0.01%	2179
2022 Q3	$0	Hold	70	–	–	﹤0.01%	3032
2022 Q2	$0	Hold	70	–	–	﹤0.01%	2891
2022 Q1	$0	Buy	+70	New	+$209	﹤0.01%	2685

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Lindbrook Capital's CTIC Position: Q2 2023 in Review

Lindbrook Capital sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 70 shares — an estimated $294 sold.

Lindbrook Capital first reported a position in CTIC in Q1 2022 and held it in 5 quarters. The position peaked at $2.25K in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Lindbrook Capital reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 70 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $294.
Lindbrook Capital first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q1 2022 and held it in 5 quarters.
Lindbrook Capital's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.25K in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.